These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 21985169)

  • 1. Current and emerging drug treatment options for Alzheimer's disease: a systematic review.
    Herrmann N; Chau SA; Kircanski I; Lanctôt KL
    Drugs; 2011 Oct; 71(15):2031-65. PubMed ID: 21985169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on Alzheimer's disease pathophysiology and its management: an update.
    Kumar A; Singh A; Ekavali
    Pharmacol Rep; 2015 Apr; 67(2):195-203. PubMed ID: 25712639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
    Schneider LS; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M
    J Intern Med; 2014 Mar; 275(3):251-83. PubMed ID: 24605808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
    Dou KX; Tan MS; Tan CC; Cao XP; Hou XH; Guo QH; Tan L; Mok V; Yu JT
    Alzheimers Res Ther; 2018 Dec; 10(1):126. PubMed ID: 30591071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].
    Franke AG; Lieb K; Fellgiebel A
    Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical treatment of Alzheimer's disease].
    Johannsen P
    Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
    Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F
    Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the rationale for new treatment strategies in Alzheimer's disease?
    Rogawski MA
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
    Cappell J; Herrmann N; Cornish S; Lanctôt KL
    CNS Drugs; 2010 Nov; 24(11):909-27. PubMed ID: 20932064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.